The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
The so-called ACT sheets are one pagers that guide doctors on what to do after receiving a genetic test results for a patient.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
The new guidance could benefit Hologic and Roche, both of which market molecular blood screening tests authorized by the FDA under an investigational new drug study protocol.
However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.
The recommendations resulted from two meetings that brought together physicians, lab workers, researchers, genetic counselors, and patient families from the US and Canada.
The recommendation calls for NIPT to be initially offered to women deemed at high risk for trisomy 21, 13, or 18 after the initial screening test.
Based on the recommendations of an expert working group, NIH hopes to begin enrolling the national research cohort of a million volunteers next year.
The recommendations address incidental findings from next-generation sequencing tests, physician education, as well as test regulation and reimbursement.
The evidence-based "Choosing Wisely" suggestions are meant to facilitate conversation between doctors and patients about unnecessary and wasteful interventions.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.